Budget impact analysis of switching to ranibizumab biosimilar for retinal diseases in Jordan
Jordan Eye Drug Biosimilar Slashes Costs and Boosts Patient Access
This budget impact analysis from a Jordanian public sector perspective estimates that switching from aflibercept to ranibizumab's biosimilar…
Switching to a biosimilar version of a common eye drug could save Jordan’s public health system millions and help more patients get treatmen…
FDA Approves Pavblu (aflibercept) for Neovascular AMD, RVO, DME, and DR
FDA approves Pavblu to treat several eye conditions that cause vision loss.
The FDA approved Pavblu (aflibercept) for neovascular AMD, macular edema following RVO, DME, and DR. It is a VEGF inhibitor administered by …
The FDA approved Pavblu (aflibercept) for wet age-related macular degeneration, macular edema, diabetic macular edema, and diabetic retinopa…
Systematic review and meta-analysis shows aflibercept biosimilars match reference drug efficacy and safety in AMD and DME
Aflibercept biosimilars match the original drug for eye disease treatment
This systematic review and meta-analysis evaluated aflibercept biosimilars versus reference aflibercept for neovascular age-related macular …
A large review of 4064 patients found that aflibercept biosimilars work just as well as the original drug for two common eye conditions.
Aflibercept 8 mg extended dosing maintains visual gains with fewer injections versus 2 mg every 8 weeks in DME
Aflibercept 8 mg every 16 weeks matches standard dosing for diabetic macular edema
This randomized, double-masked, noninferiority phase 2/3 trial enrolled 658 patients aged ≥ 18 years with center-involved diabetic macular e…
A new trial shows that aflibercept 8 mg every 16 weeks works as well as the standard 2 mg every 8 weeks for diabetic macular edema with fewe…
Post hoc analysis compares brolucizumab and aflibercept for diabetic macular edema
A New Eye Injection Works Even If You've Had Treatment Before
A post hoc analysis of a randomized trial in 517 participants with diabetic macular edema compared intravitreal brolucizumab to aflibercept …
People with diabetic eye disease who have already tried other injections may still get meaningful vision improvement from brolucizumab.
PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
Does combining these lung cancer drugs extend life, or just delay disease growth?
A meta-analysis of 2,787 patients with advanced or metastatic NSCLC found that combining PD-1/PD-L1 inhibitors with multi-targeted anti-angi…
Combining lung cancer drugs slows disease growth but offers no clear survival benefit for patients with advanced non-small cell lung cancer.
FDA Approves Eylea HD (aflibercept) for nAMD, DME, Diabetic Retinopathy, and Macular Edema Following RVO
FDA approves a new, higher-dose version of the eye medicine Eylea
The FDA has approved Eylea HD, a VEGF inhibitor, for the treatment of neovascular age-related macular degeneration, diabetic macular edema, …
FDA approves higher-dose Eylea to treat four eye conditions that damage the retina and threaten vision, potentially reducing how often patie…
Intravitreal Anti-VEGF Shows Anatomic and Visual Gains in Irvine-Gass Syndrome Meta-Analysis
Can eye injections help people with Irvine-Gass syndrome see better?
A systematic review and meta-analysis of 343 eyes with Irvine-Gass syndrome found intravitreal anti-VEGF treatment was associated with a mea…
Eye injections for Irvine-Gass syndrome reduced swelling and improved vision in most patients, though doctors still need to prove these trea…
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD
Can cheaper eye drugs work as well as expensive ones? A major review says yes for vision loss in older adults
A meta-analysis of 17 RCTs (n=6694) found no clinically meaningful differences in BCVA improvement at 12 weeks (MD=-0.42, p=0.17) or endpoin…
Cheaper eye drug copies work just as well as expensive originals for treating vision loss in older adults, a major review confirms.